9.11 ABSTRACT University of Minnesota Cancer Center (UMCC) trial review and monitoring oversight is based on NCI/NIH guidelines to ensure the safety of participants and the validity of clinical trial data. Review of protocols for scientific merit and study progress is conducted by the Cancer Protocol Review Committees (CPRC). The responsibilities of the CPRCs are distinct from those of the Data and Safety Monitoring Council (DSMC) which has oversight of monitoring activities and data validity. The CPRCs review all University of Minnesota clinical cancer protocols including investigator initiated and industry-sponsored trials. The two CPRC committees are the Intervention Trials (CPRC-TI) Committee chaired by Robert Kratzke, MD, Chair and the Non-Therapeutic Intervention Trials (CPRC-NTI) Committee chaired by Julie Ross, PhD, Chair. The CPRCs may approve or disapprove a study for lack of scientific merit or progress. The DSMG chaired by Gregory Vercellotti, MD functions independently from the IRB and oversees data, safety and monitoring of ongoing clinical cancer trials. The DSMC primarily evaluates investigatOMnitiated trials. The DSMC makes recommendations to the Clinical Research Leadership Committee (CRL) to suspend or close a trial if the risk to subjects is thought to be excessive or to outweigh potential benefits. The DSMC Chair has the authority to temporarily suspend a trial without CRL approval in situations requiring immediate action. AUcommittee chairs are appointed by the Clinical Research Leadership Committee. The Cancer Center Clinical Trials office administratively supports the three committees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-15
Application #
8450011
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$106,643
Indirect Cost
$36,018
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarver, Aaron L; Murray, Collin D; Temiz, Nuri A et al. (2016) MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle 15:881-5
Diep, Caroline H; Knutson, Todd P; Lange, Carol A (2016) Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res 14:141-62
Yun, Young Sung; Kim, Kwan Hyun; Tschida, Barbara et al. (2016) mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell 61:625-39
Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42
Beura, Lalit K; Hamilton, Sara E; Bi, Kevin et al. (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-6
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Struntz, Nicholas B; Harki, Daniel A (2016) Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors. ACS Chem Biol 11:1631-8
Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33
Glasgow, Michelle; Vogel, Rachel Isaksson; Burgart, Jennifer et al. (2016) Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol Res Pract 3:6
Felices, Martin; Lenvik, Todd R; Davis, Zachary B et al. (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol 1441:333-46

Showing the most recent 10 out of 763 publications